Skip to main content
CING
NASDAQ Life Sciences

Cingulate Q3 10-Q: $23.2M Cash, $7.7M Quarterly Loss, Going Concern Restated

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.25
Mkt Cap
$62.53M
52W Low
$3.16
52W High
$11.89
52W Position info
34% above low
Off High info
64% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

CING sits 34% above its 52-week low of $3.16.

Summary

Cingulate's Q3 10-Q shows $23.2 million of cash, a $7.7 million quarterly net loss and a restated going-concern warning, with the runway into mid-2027 dependent on continued ATM and equity-line sales.


Key Events · Earnings and Guidance · CING

  • Q3 Loss and Cash Position

    Net loss was $7.7 million for the quarter and $22.9 million for the nine months; cash and cash equivalents stood at $23.2 million at September 30, 2026 versus $11.0 million at December 31, 2025.

  • Going Concern Doubt Restated

    Management states substantial doubt about the Company's ability to continue as a going concern within one year after the financial statements are issued, with an accumulated deficit of $155.3 million.

  • Cash Burn Versus Financing

    Operating activities used $20.2 million in the first nine months while financing activities provided $32.6 million, including $34.3 million of net stock and warrant proceeds.

  • SG&A Doubles on Launch Prep

    SG&A rose 116.5% to $14.2 million for the nine months, including $7.2 million of pre-commercialization costs, while R&D fell 15.3% to $6.6 million.


Analysis · CING · Life Sciences

The 10-Q puts hard numbers behind the same-day earnings 8-K and repeats the going-concern warning that has hung over Cingulate since its last quarterly report. Cash of $23.2 million at September 30 is up from $11.0 million at year-end 2025, but that came from $34.3 million of net financing proceeds against $20.2 million of operating cash burn, and management still says substantial doubt exists about continuing as a going concern within a year of issuance. The spending mix has shifted toward launch preparation: SG&A more than doubled to $14.2 million for the nine months, including $7.2 million of pre-commercialization costs, while R&D fell 15.3% to $6.6 million. The company's own runway statement extends into mid-2027, which overlaps the targeted December 2026-January 2027 CTx-1301 NDA resubmission, so the financing treadmill has to keep turning until the FDA acts.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CING was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.5M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CING - Latest Insights

CING
Nov 13, 2026, 5:19 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $4.25 info
Change: $0 (0%) info
Market Cap: $62.53M info
CING
Nov 10, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $4.25 info
Change: -$0.500 (-11%) info
Market Cap: $62.53M info
CING
Aug 13, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $4.25 info
Change: -$0.870 (-17%) info
Market Cap: $62.53M info
CING
Aug 13, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.12
Real-time Price: $4.25 info
Change: -$0.870 (-17%) info
Market Cap: $62.53M info
CING
Jul 02, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.90
Real-time Price: $4.25 info
Change: -$1.65 (-28%) info
Market Cap: $62.53M info